pancreatitis
Reading File
search_medical_text
pancreatitis etiology diagnosis classification severity
search_medical_text
pancreatitis management treatment complications
search_medical_image
pancreatitis CT imaging findings
GradeResponse
GradeResponse
GradeResponse
Here is a comprehensive overview of pancreatitis:
Pancreatitis
Etiology
The two most common causes account for ~80% of cases:
| Cause | Details |
|---|---|
| Gallstones | Most common overall; gallstone migrating through the ampulla of Vater causes transient obstruction |
| Alcohol | Second most common; typically requires years of heavy use |
| Hypertriglyceridemia | Usually >1000 mg/dL; third most common |
| ERCP | Post-procedural pancreatitis (3–5% of cases) |
| Drugs | Azathioprine, thiazides, furosemide, valproate, tetracyclines, etc. |
| Infections | Mumps, CMV, Coxsackievirus |
| Autoimmune | IgG4-related (Type 1) or IDCP (Type 2) |
| Hereditary | PRSS1, SPINK1, CFTR mutations |
| Idiopathic | ~10–20% of cases |
Clinical Presentation
- Pain: Epigastric, often radiating to the back; constant, boring in character; worsens supine, may improve leaning forward
- Nausea and vomiting: Almost universal
- Fever and tachycardia: Common in moderate-severe disease
- Grey Turner's sign (flank ecchymosis) and Cullen's sign (periumbilical ecchymosis): Rare but indicate hemorrhagic pancreatitis
Diagnosis
Lab findings:
- Serum amylase >3× ULN or serum lipase >3× ULN (lipase is more sensitive and specific)
- Elevated WBC, CRP, LDH, bilirubin (if biliary cause)
- Elevated creatinine (if AKI develops)
Imaging:
- Ultrasound (US): First-line to identify gallstones and biliary dilation
- CT abdomen (contrast-enhanced): Gold standard for severity assessment; best performed 48–72 hours after symptom onset if diagnosis is unclear or severity is in question
CT Imaging: Necrotizing Pancreatitis
Axial contrast-enhanced CT showing enlarged, heterogeneous pancreas with areas of non-enhancement (necrosis), retroperitoneal air, peripancreatic fluid collections, and evolution into walled-off necrosis (WON).
Severity Classification (Revised Atlanta 2013)
| Category | Definition |
|---|---|
| Mild | No organ failure, no local/systemic complications; resolves within 1 week |
| Moderately Severe | Transient organ failure (<48 h) and/or local complications |
| Severe | Persistent organ failure (>48 h); single or multi-organ |
Scoring systems (Bailey & Love, p. 1292):
- Ranson criteria: Scored at admission + 48 h; ≥3 = severe
- Glasgow (Imrie) score: ≥3 at 48 h = severe
- APACHE II: Can be applied throughout admission
- CRP >150 mg/L at 48 h: Independent severity marker
- BMI >30: Higher risk of complications
Management
Per Harrison's (p. 9730): 85–90% of cases are self-limited, resolving within 3–7 days.
Mild Pancreatitis
- IV fluid resuscitation: Lactated Ringer's preferred over NS (reduces SIRS); 250–500 mL/hr initially
- NPO initially, then early oral feeding as tolerated (within 24–48 h if possible)
- Analgesia: IV opioids (morphine, hydromorphone); multimodal approaches preferred
- Monitoring: Vitals, urine output, labs (BMP, CBC)
Moderate-Severe / Severe Pancreatitis
- ICU-level care if persistent organ failure
- Aggressive fluid resuscitation with close monitoring
- Enteral nutrition (nasojejunal feeding) preferred over TPN; start within 24–72 h
- ERCP: Urgent (<24–72 h) if cholangitis or persistent biliary obstruction
- Antibiotics: NOT prophylactic; only indicated for confirmed infected necrosis
- Surgical/interventional: Step-up approach for infected or symptomatic necrosis — percutaneous drainage → endoscopic/surgical debridement (necrosectomy)
Local Complications
| Complication | Description |
|---|---|
| Acute peripancreatic fluid collection (APFC) | Early (<4 weeks), no defined wall |
| Pseudocyst | Fluid collection with defined wall, >4 weeks, no solid component |
| Acute necrotic collection (ANC) | Early necrosis with fluid and solid material |
| Walled-off necrosis (WON) | Mature, encapsulated necrosis, >4 weeks |
| Infected necrosis | Fever, elevated WBC, gas on CT; requires intervention |
Systemic Complications
- ARDS (most common cause of early death)
- AKI
- DIC
- Hypocalcemia (saponification of fat)
- Hyperglycemia
- Pleural effusions
Chronic Pancreatitis
Distinct from acute: characterized by irreversible fibrosis, ductal changes, and progressive exocrine/endocrine insufficiency.
- Triad: Chronic epigastric pain, steatorrhea, diabetes mellitus
- Imaging: Pancreatic calcifications (pathognomonic), dilated main pancreatic duct
- Management: Pain control (stepwise), pancreatic enzyme replacement therapy (PERT), treat diabetes, alcohol/smoking cessation, endoscopic or surgical decompression in selected cases
Key take-home points:
- Lipase is the preferred diagnostic enzyme
- Revised Atlanta 2013 guides severity stratification
- Most cases are mild and self-limiting; aggressive early fluids are the cornerstone of treatment
- Antibiotics are not routine; reserve for proven infected necrosis
- Early enteral nutrition is superior to TPN in severe disease
history: 50y male postptca patient ef 40% , k/c/o dm/htn , p/w h/o fever 5 days a/w chills and rigors , malaria falciparum antigen positive , on norad infusion single strength @5ml/hr nibp 112/80. hr 150 , tacypnea rr of 30-40 , abg s/o ph 7.462 pco2 25, po2 71 na 131 k 3.8 ca 1.16 glucose 207 so2 88.6 anion gap 3.7 , hfnc trial given switched to niv . differential , plan of treatment, tests ...
search_medical_text
severe malaria falciparum management ICU treatment artemisinin
search_medical_text
malaria falciparum respiratory failure ARDS hypoxemia mechanical ventilation
search_medical_text
septic shock norepinephrine hemodynamic management low EF cardiac dysfunction
GradeResponse
GradeResponse
Critical Illness Summary
50M | Post-PTCA (EF 40%) | DM/HTN | Severe Falciparum Malaria with Septic Shock + Respiratory Failure on NIV
ABG Interpretation
| Parameter | Value | Interpretation |
|---|---|---|
| pH | 7.462 | Alkalotic |
| pCO₂ | 25 mmHg | Low → respiratory alkalosis |
| PaO₂ | 71 mmHg | Hypoxemia |
| Na | 131 | Hyponatremia |
| K | 3.8 | Normal |
| Ca (ionized) | 1.16 | Low-normal |
| Glucose | 207 | Hyperglycemia |
| SpO₂ | 88.6% | Significant hypoxemia |
| Anion Gap | 3.7 | Low (hypoalbuminemia likely) |
Primary disorder: Respiratory alkalosis — driven by hypoxemia-induced hyperventilation (RR 30–40). The low anion gap suggests hypoalbuminemia (correct AG: add 2.5 × [4 − albumin] for true AG). Metabolic acidosis may be masked — obtain lactate urgently.
PaO₂/FiO₂ ratio (assuming FiO₂ ≥0.5 on HFNC/NIV): likely <200 → Moderate-Severe ARDS by Berlin criteria.
Differentials for Fever + Respiratory Failure in This Context
| Diagnosis | Likelihood | Key Pointer |
|---|---|---|
| Severe Falciparum Malaria (ARDS + Shock) | ✅ Primary | Positive antigen, multi-organ involvement |
| Superimposed Bacterial Sepsis / CAP | ✅ High | Fever, chills, rigors, shock, tachypnea |
| Malaria-induced Myocarditis / Cardiac Decompensation | ✅ Moderate | EF 40%, post-PTCA, HR 150 |
| Falciparum Malaria Pulmonary Edema | ✅ Moderate | Distinct from ARDS; fluid overload risk high in low-EF |
| HCAP / Ventilator-associated | Moderate | Nosocomial risk |
| COVID-19 / Viral co-infection | Lower | Worth excluding |
| Hyperglycemic crisis contribution | Present | Glucose 207, osmotic effects |
Criteria for Severe Malaria (this patient meets multiple):
- ✅ Respiratory distress / ARDS
- ✅ Circulatory collapse (on norepinephrine)
- ✅ Impaired consciousness (assess GCS)
- Hyperparasitemia (>5%) — check smear urgently
- Hypoglycemia — monitor closely (glucose 207 currently, but can drop rapidly with artesunate + quinine)
- Renal failure — check creatinine
- Jaundice — check bilirubin
- Abnormal bleeding — check PT/aPTT
Investigations — Urgent
Immediate (Stat)
| Test | Purpose |
|---|---|
| Peripheral smear (thick + thin) | Confirm species, quantify parasitemia % |
| Serum lactate | Unmask occult metabolic acidosis, severity |
| CBC with differential | Hemolytic anemia, thrombocytopenia (hallmark of falciparum) |
| LFTs + bilirubin | Jaundice, hepatic malaria |
| Serum creatinine, BUN, urine output | Acute kidney injury (major complication) |
| PT/aPTT/INR, fibrinogen, D-dimer | Coagulopathy, DIC |
| Serum albumin | Correct anion gap, guide nutrition |
| Blood cultures ×2 | Gram-negative bacteremia co-infection |
| Procalcitonin | Bacterial co-infection |
| NT-proBNP / BNP | Cardiac function, volume status |
| Repeat ABG in 1–2 hrs | NIV response monitoring |
| CXR (portable) | Bilateral infiltrates (ARDS vs pulmonary edema) |
| Serum glucose Q2H | Hypoglycemia risk (especially with quinine) |
| Urine RE/ME | Hemoglobinuria ("blackwater fever") |
Within 12–24 Hours
| Test | Purpose |
|---|---|
| ECHO (bedside) | EF reassessment, RV strain, volume status |
| Malaria parasitemia Q12H | Treatment response |
| Repeat electrolytes | Hyponatremia, K+ monitoring |
| G6PD deficiency screen | Before primaquine/radical cure |
| HIV, HBsAg | Baseline immune/co-infection workup |
| Chest HRCT (if CXR equivocal) | ARDS characterization |
| Urinary catheter + strict I/O | Volume management critical in low EF |
Treatment Plan
1. Anti-malarial (Priority 1)
IV Artesunate — drug of choice for severe falciparum malaria (Harrison's, p. 6446; reduces mortality by 35% vs quinine)
- Dose: 2.4 mg/kg IV at 0, 12, 24 hours, then once daily until oral therapy possible
- Transition to oral Artemisinin-based Combination Therapy (ACT) once tolerating orals:
- Artemether-Lumefantrine (Coartem) OR
- Artesunate + Mefloquine / Doxycycline
- Monitor glucose Q2H — artesunate-associated delayed hemolysis can occur; watch Hb from day 7–28
- Avoid quinine if possible (QTc prolongation risk in post-PTCA patient)
2. Respiratory Management
Currently on NIV — continue with close monitoring:
| Parameter | Target |
|---|---|
| SpO₂ | ≥94% |
| RR | <25/min |
| Work of breathing | Decreasing |
| GCS | ≥12 (NIV safety threshold) |
- NIV settings: IPAP 12–16 cmH₂O, EPAP 8–10 cmH₂O, FiO₂ titrate to SpO₂
- Reassess in 1–2 hours — if no improvement (SpO₂ <90%, RR unchanged, worsening sensorium) → early intubation with lung-protective ventilation
- Tidal volume 6 mL/kg IBW
- PEEP 8–12 cmH₂O (titrate via P-V tool or empiric)
- Plateau pressure <30 cmH₂O
- Prone positioning if PaO₂/FiO₂ <150 despite optimization
- Caution with fluids: EF 40% + ARDS = high risk of flash pulmonary edema; target conservative fluid strategy guided by BNP + ECHO
3. Hemodynamic / Vasopressor Management
- Norepinephrine already running — titrate to MAP ≥65 mmHg (or ≥70 mmHg given EF 40%)
- If norad >0.25 mcg/kg/min → add Vasopressin 0.03 units/min (vasopressor-sparing, reduces norad dose)
- Dobutamine: Consider if low cardiac output state (post-PTCA, EF 40%, cold peripheries, high lactate) — start 2.5–5 mcg/kg/min
- Avoid volume loading — high risk of pulmonary edema in EF 40%
- Check ECHO urgently to differentiate:
- Distributive shock (warm, low SVR) — malaria/sepsis
- Cardiogenic component (cold, low CO) — EF 40% decompensation
4. Fluid & Electrolyte Management
| Issue | Action |
|---|---|
| Hyponatremia (Na 131) | Likely dilutional/SIADH in severe malaria; restrict free water; correct slowly; avoid aggressive NS (hyperchloremia risk) |
| Hypocalcemia (Ca 1.16) | Replace IV calcium gluconate if symptomatic or worsening; monitor ECG |
| Hyperglycemia (207) | IV insulin infusion targeting 140–180 mg/dL; avoid hypoglycemia aggressively |
| Hypokalemia risk | K⁺ 3.8 currently — monitor closely, replace if drops <3.5 |
| Fluids | Use balanced crystalloids (LR preferred); strict I/O; urine output target >0.5 mL/kg/hr |
5. Antibiotic Cover
- Start empiric broad-spectrum antibiotics given septic shock picture (cannot exclude bacterial co-infection):
- Piperacillin-Tazobactam 4.5g IV Q6H (or Meropenem if high ESBL risk)
- +/- Azithromycin (covers atypicals, also has anti-malarial properties)
- De-escalate based on cultures at 48–72 hours
6. Cardiac Monitoring & Protection
- Continuous ECG monitoring (QTc — especially relevant for any anti-malarial)
- Avoid QTc-prolonging drugs wherever possible
- Statin continuation (if on one for post-PTCA)
- Hold ACE inhibitor / ARB if hypotensive
- Aspirin: Continue if on it post-PTCA, assess bleeding risk vs. thrombotic risk
- Beta-blocker: Hold or reduce if hemodynamically unstable / HR 150 with shock; re-evaluate once stable
- HR 150 — rule out AF with RVR (common in sepsis + malaria): 12-lead ECG urgently; if AF → rate control cautiously (amiodarone preferred in low EF)
7. Additional Supportive Care
| Issue | Intervention |
|---|---|
| DVT prophylaxis | Mechanical (pneumatic compression) initially; anticoagulate once bleeding risk assessed |
| Stress ulcer prophylaxis | IV PPI (pantoprazole) |
| Glycemic control | IV insulin infusion; Q1–2H glucose monitoring |
| Nutrition | Early enteral nutrition via NG once hemodynamically stable |
| Renal monitoring | Foley catheter in-situ; if AKI develops → consider RRT early |
| Transfusion | If Hb <7 g/dL (or <8 in cardiac patient); falciparum causes significant hemolysis |
| Platelet transfusion | If <10k (or <50k with active bleeding); thrombocytopenia expected |
Red Flags to Watch — Deterioration Triggers
| Sign | Action |
|---|---|
| SpO₂ <90% on NIV / worsening WOB | Intubate immediately |
| GCS drop | Cerebral malaria — intubate, urgent CT head |
| Urine output <0.5 mL/kg/hr | Aggressive AKI workup, early RRT |
| Glucose <70 mg/dL | IV dextrose bolus; adjust insulin |
| MAP <65 on ≥0.25 mcg/kg/min norad | Add vasopressin ± dobutamine |
| Worsening coagulation | Manage DIC — FFP, cryoprecipitate |
| New hemoglobinuria (dark urine) | Blackwater fever — aggressive hydration, avoid quinine |
Summary of Immediate Priorities
- IV Artesunate — start immediately (do not delay for investigations)
- Peripheral smear — confirm parasitemia %
- Serum lactate + cultures + CBC — stat
- NIV optimization — reassess in 1–2 hrs; low threshold to intubate
- Bedside ECHO — differentiate distributive vs. cardiogenic shock
- Broad-spectrum antibiotics — empiric cover
- 12-lead ECG — rule out AF, QTc monitoring
- Strict glycemic control and I/O monitoring
This is a shared conversation. Sign in to Orris to start your own chat.